Lakefront Biotherapeutics NV current report, Q1 FY2026

Business Context and Reporting Period

This Form 6-K filing by Galapagos NV (a foreign private issuer) covers the month of March 2026. The filing serves to distribute the Company's 2025 Annual Report and convene notices for the Annual and Extraordinary Shareholders' Meetings scheduled for April 28, 2026, in Mechelen, Belgium. The registrant is incorporated in Belgium and files annual reports on Form 20-F.

Key Financial Metrics

The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached 2025 Annual Report (Exhibit 99.3) and Non-Consolidated Annual Accounts (Exhibit 99.6), which are incorporated by reference but not detailed in the cover document text.

Material Changes

No material financial changes or comparative period data are disclosed in the text of this Form 6-K. The filing focuses on the procedural distribution of the 2025 annual results and shareholder meeting logistics rather than specific period-over-period financial analysis.

Guidance, Outlook, and Risks

The filing incorporates by reference the 2025 Annual Report and two press releases issued on March 26, 2026 (Exhibits 99.1 and 99.2), which likely contain management commentary, outlook, and risk factors. The text explicitly notes that certain exhibits are furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act. No specific guidance or risk descriptions are present in the cover letter text.

Investor Verification Checklist

  • Review Exhibit 99.3 (2025 Annual Report) for actual revenue, net income, and cash flow figures.
  • Examine Exhibits 99.1 and 99.2 (Press Releases) for specific updates on clinical trials, partnerships, or strategic shifts.
  • Verify the agenda and voting instructions for the Shareholders' Meetings on April 28, 2026, via Exhibits 99.4 through 99.13.
  • Confirm the status of the authorized capital mandate renewal discussed in Exhibit 99.8.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.